Bafna Pharmaceuticals Ltd
NSE: BAFNAPH BSE: 532989
₹106.15
(0.81%)
Wed, 11 Mar 2026, 10:01 am
Market Cap2.54B
PE Ratio25.99
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1981
- Bafna started as a Proprietorship concern.
1984
- Bafna set up its first manufacturing unit at Madhavaram with tablet line of installed capacity of 420 Lacs p.a.
1987
- Bafna added Capsules Line with installed capacity of 300 lacs p.a.
1990
- Bafna added Liquid Line with installed capacity of 45,000 ltr. p.a.
- Bafna made its first supplies to Government of Tamilnadu.
1994
- Bafna started Contract Manufacturing activity for Crossland Laboratories.
- Bafna received WHO GMP Certification for Madhavarm Unit.
- Bafna made its first export to Srilanka.
1995
- Bafna was incorporated with the Registrar of Companies Tamilnadu.
- Bafna started supply to ESI corporation.
2003
- Bafna Pharmaceuticals received Export House Status by Ministry of Commerce & Industry.
2005
- Bafna Pharmaceuticals received Best Supplier Award by State Pharmaceuticals Corporation of Sri Lanka.
- Bafna Pharmaceuticals started construction of new plant at Grantlyon village.
- Madhavaram Plant was approved as per revised Schedule ‘M’.
2006
- Bafna Pharmaceuticals registered 4 products in Ukraine.
- Bafna Pharmaceuticals inaugurated its new plant at Grantlyon.
- Bafna Pharmaceuticals received ISO 9001: 2000 certificate.
2007
- Bafna Pharmaceuticals received accreditation from Ghana Inspectors.
- Bafna Pharmaceuticals was rated as SE2A by Dun & Bradstreet.
- Bafna Pharmaceuticals received Manufacturing Licence for Grantlyon Unit.
- Bafna Pharmaceuticals received WHO GMP Certification for Grantlyon Unit.
2008
- Bafna Pharmaceuticals entered the capital market with its IPO.
- Bafna Pharmaceuticals received MHRA approval from UK for the Company's new plant at Grantlayon, Chennai.
2009
- Bafna Pharmaceuticals received ISO 9001: 2000 Certificate of Registration for Manufacture and Export of Pharmaceutical products.
- Bafna Pharmaceuticals received MHRA Certificate of GMP Compliances of Manufacturer from Medicines and Healthcare products Regulatory Agency, U.K.
2010
- Bafna Pharmaceuticals was awarded the Gold Quality Excellence Award 2009.
- Bafna Pharmaceuticals inaugurated its Formulation Research & Development unit in Chennai.
2011
- Bafna Pharmaceuticals received Indian Drug Manufacturer's Association Quality Excellence Award 2010 - Silver Award.
- Bafna Pharmaceuticals received Udyog Rattan Award and Excellence Award from the Institute of Economic Studies Delhi.
- Bafna Pharmaceuticals signed an agreement with NR Jet for acquisition of the TradeMark RARICAP.
2013
- Bafna Pharmaceutical launched RARICAP injection in domestic market.
- Bafna Pharmaceuticals received product approval for Ghana.
- Bafna Pharmaceuticals Ltd recommended a final dividend of Rs. 0.60 per equity share.
- Bafna Pharmaceutical launched new products Afenac, Nocaf, Izabof in domestic market.
2014
- Bafna Pharmaceuticals has appointed RS Gowdhaman as Company Secretary & Compliance Officer.
2023
- Bafna Pharmaceuticals Limited awarded with MSME-ZED certified GOLD CERTIFICATE.
2024
- The Company received All-Round Silver Star - Export Performance Award by Pharmaceuticals Export Promotion Council of India.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800